ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / GELS
BGMS (36) PCSA (39) LGVN (27) PULM (36) ⌘ Pro Terminal →

Gelteq Limited (GELS) — RQD Stock Rating Cockpit

$0.49 -3.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.49

Gelteq Limited (GELS) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $5.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GELS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GELS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Gelteq Limited (NASDAQ: GELS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $0.49 (-3.14% 1D, market cap $5.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GELS ranks #250 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GELS compare to BGMS and PCSA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GELS carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, GELS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GELS?
▼

For Gelteq Limited (GELS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #250 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.49 (-0.76%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Cash (12)Whales (11)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE GELS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GELS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY GELS SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($151.8K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$0.49-12.2% Next Q
Q2 (-2Q)
49
Grade D$0.43+4.7% Next Q
Q3 (-1Q)
51
Grade C-$0.45+8.9% Next Q
Current
54
Grade D+$0.49-0.7% Hist 90D α
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GELS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GELS currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.56) and Max Pain ($0.51) forces dealer call-delta covering toward $2.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GELS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GELS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
51.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE6% OF RANGE
L: $0$0.49H: $2
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on GELS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (48)

20/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like GELS
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GELS)

  • ✓Walkthrough of GELS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GELS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.33%⚡ TESTING RESISTANCE
2026-11-02O $0.49H $0.51L $0.49C $0.49VOL 77.2K
RES: $0.51SUP: $0.43SMA50: $0.56SMA200: $0.66
$2.12$1.65$1.18$0.71$0.24RES $0.51SUP $0.43$0.492026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GELS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GELS Butterfly Map → + Track GELS →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GELS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GELS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GELS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GELS)

Health Care Rank #250 of 1016 ⚔️ BGMS vs GELS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GELS vs. BGMS, PCSA, LGVN, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Gelteq Limited (GELS) ranks #250 by composite RQD confidence (54/100, grade D+) and #938 by equity capitalization ($5.4M). Within this direct 5-issuer industry benchmark cohort, GELS leads on earnings valuation at N/A trailing P/E, while BGMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GELS ACTIVE
Gelteq Limited
D+ 54/100 — — — -3.14% $5.4M Benchmark Subject
BGMS
Bio Green Med Solution Inc.
D- 36/100 — — -35.0% +8.43% $5.5M /bgms-vs-gels →
PCSA
Processa Pharmaceuticals Inc.
D- 39/100 — — -35.0% 0.00% $5.3M /pcsa-vs-gels →
LGVN
Longeveron Inc. (Class A)
E 27/100 — 67.0% -35.0% -4.57% $5.6M /lgvn-vs-gels →
PULM
Pulmatrix Inc.
D- 36/100 — — -35.0% -1.06% $5.2M /pulm-vs-gels →

2. GELS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Gelteq Limited (GELS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GELS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GELS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Gelteq Limited (NASDAQ: GELS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $0.49 (-3.14% 1D, market cap $5.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GELS ranks #250 in composite RQD confidence.

How does GELS compare to BGMS and PCSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GELS carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, GELS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GELS?

For Gelteq Limited (GELS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #250 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GELS trading relative to its 50-day, 200-day, and 52-week technical levels?

GELS last traded at $0.49 (-3.14% on volume of 26,155 shares), positioning the stock -12.50% below its 50-day simple moving average ($0.56) and -25.76% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.39 to $2.01, GELS sits at the 6.2% percentile with a 14-day RSI of 51.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.55).

GELS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell GELS stock right now?

Gelteq Limited (GELS) currently earns a Roarable Rating of D+ (Sell — SELL) with 54/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is GELS's 12-month price target and RQD AI Jury consensus?

GELS's 12-month base price target is $0.48 (range $0.37 to $2.11), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: GELS RQD Cockpit GELS 12M Forecast GELS Earnings & Move GELS Dividends & DRIP GELS Insiders & 13F GELS Whale Options GELS Profit Sankey GELS News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GELS — Gelteq Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:20:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GELS scores 54 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

  • Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). This is the weakest read on earnings power: the source data shows no return on invested capital and no free cash flow yield.
  • Whale 13F Flow: 11 / 20 (institutional accumulation and options positioning). This pillar reflects a modest institutional signal, but the holders section contains no underlying holder data to verify it.
  • Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is a below-midpoint reading, indicating limited insider-side conviction in the source data.
  • Macro Regime Fit: 9 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock moves in line with the market; the score reflects limited regime-fit support.
  • Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, indicating a comparatively stable balance sheet relative to the other four.

For a prospective investor, the upside case rests mainly on balance-sheet stability and the institutional-flow signal, while the valuation tradeoff is stark: with a 0% ROIC, 0% FCF yield, and no reported margins, the stock's current price of 0.51 is not supported by cash-generation metrics in the source data. The verdict label's "Trim" language signals that the rating framework views the fundamentals as weak. Momentum-driven price moves (a 5.11% change on the day, with a 52-week range of $0.39 - $2.01) should be weighed against these fundamental gaps.

Recent Catalysts & News Wire Analysis

The news wire contains six items, all tagged to GELS. Five are marked YELLOW (MARKET WIRE) and one is marked RED (RISK WATCH):

  • Multiple aggregated reports (TradingView, Yahoo Finance UK, Yahoo! Finance Canada) cover GELS market action, institutional positioning, and fundamental catalysts, though several headlines reference a different ticker (QNME, RDHL), which limits their specificity.
  • A momentum-oriented headline reports GELS shares trading at $0.53, described as an edge higher.
  • The RISK WATCH item concerns a Q2 2026 earnings report for a company identified as "NOA," with the headline stating EPS missed estimates despite a positive stock reaction and including a revenue guidance update. The source attributes this item to GELS, but the company name in the headline does not match Gelteq Limited, so the attribution cannot be confirmed from the data provided.

The Butterfly Supply-Chain Graph lists supply chain as NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What products or services does Gelteq generate revenue from, and who are its customers?
  • What are the reported revenue, operating income, net income, and free cash flow for recent periods, given that the financials section is empty?
  • Which company does the RISK WATCH earnings item ("NOA" Q2 2026 EPS miss) refer to, and does it apply to GELS at all?
  • What do the 13F institutional holdings and insider Form 4 filings actually show, given that the holders section is empty?
  • What is the basis for the reported 0% ROIC and 0% FCF yield, and are these values accurate or placeholders?

GELS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Gelteq Limited (GELS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GELS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GELS Bull vs. Bear Conversation Board — What's Your Call at $0.49?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GELS 🐻 50% BEARISH CONVICTION
1. Pick Your Side on GELS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.55 (+7.8%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GELS (D+ • RQD 54/100) a Buy at $0.51?

Welcome to the GELS (Gelteq Limited) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.42 (-17.6%)
Spot @ $0.51

Pump the brakes on GELS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GELS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Gelteq Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.61 (+19.6%)
Spot @ $0.51

GELS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GELS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.51 (52-wk range $0.39 - $2.01), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%